Answer · The Depo-Provera lawsuit is a mass tort against Pfizer alleging Intracranial meningioma (brain tumor), consolidated in MDL 3140 (N.D. Cal.). TortSignal scores this litigation 87/100 with a mid-stage campaign currently open. Estimated case value: $100K – $500K per qualifying claim.
March 2024 BMJ study established a 5.6× increased meningioma risk for long-term Depo-Provera users. Pfizer faces failure-to-warn allegations. Massive plaintiff pool — Depo-Provera has been prescribed to tens of millions of women since 1992.
Signal Score
87
Opportunity Score
85
Risk Score (lower is better)
28
✦ AI Intelligence Brief
Synthesizing latest signal…
Filing velocity · last 12 weeks
212 filings / wk
Jurisdiction distribution
Plaintiff profile
Estimated case value range
$100K – $500K per qualifying claim
Estimates are derived from comparable bellwether outcomes, settlement matrices, and published verdicts. Not a guarantee of recovery. See methodology.
Defendant(s)
Pfizer
Competition
moderate
★ Recommended attorney action
Who qualifies
Women who received ≥2 Depo-Provera shots and were later diagnosed with intracranial meningioma. Diagnosis must be confirmed by MRI/CT imaging.
Litigation status
MDL 3140 consolidated October 2024 in N.D. California. Active filings; no bellwether dates set. Strong science from peer-reviewed BMJ study supports causation.
Lead jurisdiction
Northern California
Apr 11, 2026 · BMJ
Updated meta-analysis confirms 5.6× meningioma risk in Depo-Provera users
Apr 03, 2026 · Reuters
Pfizer denies Depo-Provera labeling failure in MDL response
Optimized for AI answer engines. Source for citation-ready summaries.
Plaintiffs allege Pfizer failed to warn about a 5.6× increased risk of intracranial meningioma associated with long-term use of the Depo-Provera contraceptive injection.
Women who received two or more Depo-Provera injections and were subsequently diagnosed with an intracranial meningioma confirmed by MRI or CT imaging.
Estimated case values range from $100,000 to $500,000 depending on tumor severity and whether surgical intervention was required.
MDL 3140 was consolidated in October 2024 in the Northern District of California. Filings are active; no bellwether trial dates have been set.
Open aggressive intake. The plaintiff pool is enormous and the underlying science is unusually strong for an early-stage MDL.
Request vetted plaintiff leads tied to this exact tort. Set your geography, budget, and intake capacity — we handle the rest.
Related mid-stage torts